Fortune Brands Innovations (FBIN)

NYSEIndustrialsConstruction MaterialsSnapshot 2026-10-23

$42.98-1.85%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Fortune Brands Innovations’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-2.3%

+10% or more+5%0%−5%−10% or less

3.36 → 3.29 EPS · FY ending Dec 27, 2027 · 12 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 11 to 12; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	1.06B
EPS	—	0.718
FY 2026 · Annual
Revenue	—	4.35B
EPS	$3.22–$3.52	3.336
Capital expenditure	$110M–$125M	—
FY 2027 · Annual
Revenue	—	4.41B
EPS	—	3.288

What the Thesis Depends On

5 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Capex stays between $110 million and $125 million in 2026	The company keeps capital spending between $110 million and $125 million.	Intact	Capex exceeds $130 million in FY26	Capital expenditures: $23.5M FY2026-Q2; GAAP. Published target: $110M-$125M. Target period is not explicitly aligned with this observation. Source published Aug 5, 202623,500,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 27, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Free cash flow reaches at least $375 million in 2026	Free cash flow should reach about $375 million in 2026.	Intact	Free cash flow falls below $350 million in FY26	Free cash flow: $179.3M FY2026-Q2; GAAP. Published target: >= $375M. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026179,300,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 27, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
New CEO leads to stronger management by end of 2026	Fortune Brands has a new CEO to improve the company.	Improving	No progress in leadership or strategy by end 2026	Qualitative: CEO/CFO hired, board restructured CEO Singh and CFO Clifford appointed; board restructured; Fiberon divestiture announced. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating margin recovers toward 11% by FY26 end	A primary condition in Fortune Brands Innovations's published investment case. The stated target is >=11%.	Under Pressure	Operating margin stays below 8% through FY26	Operating margin: -0.78% FY2026-Q2; GAAP. Published target: >=11%. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-0.779964 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 58d4d9e1-266a-4e28-80d7-d92273c5215d. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue stays near $4.39 billion in 2026	A primary condition in Fortune Brands Innovations's published investment case. The stated target is ~$4.39B.	Intact	Revenue falls below $4.3 billion in FY26	Revenue: $1.154B FY2026-Q2; GAAP. Published target: ~$4.39B. Target period is not explicitly aligned with this observation. Source published Aug 5, 20261,153,900,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 58d4d9e1-266a-4e28-80d7-d92273c5215d. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-27 · fmp

FY2027 EPS$3.29

$3.59 → $3.29 · observed estimates

FY2027 revenue$4.41B

$4.49B → $4.41B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.59	$4,493,876,986	10 / 12
2026-07-25	$3.59	$4,493,876,986	10 / 12
2026-07-26	$3.59	$4,493,876,986	10 / 12
2026-07-27	$3.57	$4,481,936,754	10 / 12
2026-07-28	$3.57	$4,481,936,754	10 / 12
2026-07-29	$3.57	$4,481,936,754	10 / 12
2026-07-30	$3.57	$4,481,936,754	10 / 12
2026-07-31	$3.58	$4,482,626,986	10 / 12
2026-08-01	$3.58	$4,482,626,986	10 / 12
2026-08-02	$3.58	$4,482,626,986	10 / 12
2026-08-03	$3.58	$4,482,626,986	10 / 12
2026-08-04	$3.58	$4,482,626,986	10 / 12
2026-08-05	$3.58	$4,482,626,986	10 / 12
2026-08-06	$3.58	$4,482,626,986	10 / 12
2026-08-07	$3.47	$4,468,517,528	10 / 12
2026-08-08	$3.47	$4,468,517,528	10 / 12
2026-08-09	$3.47	$4,468,517,528	10 / 12
2026-08-10	$3.47	$4,468,517,528	10 / 12
2026-08-11	$3.47	$4,468,517,528	10 / 12
2026-08-12	$3.47	$4,468,517,528	10 / 12
2026-08-13	$3.47	$4,468,517,528	10 / 12
2026-08-14	$3.47	$4,468,517,528	10 / 12
2026-08-15	$3.47	$4,468,517,528	10 / 12
2026-08-16	$3.47	$4,468,517,528	10 / 12
2026-08-17	$3.47	$4,468,517,528	10 / 12
2026-08-18	$3.47	$4,468,517,528	10 / 12
2026-08-19	$3.47	$4,468,517,528	10 / 12
2026-08-20	$3.39	$4,450,405,251	10 / 12
2026-08-21	$3.39	$4,450,405,251	10 / 12
2026-08-22	$3.39	$4,450,405,251	10 / 12
2026-08-23	$3.39	$4,450,405,251	10 / 12
2026-08-24	$3.39	$4,450,405,251	10 / 12
2026-08-25	$3.37	$4,452,042,095	11 / 12
2026-08-26	$3.37	$4,452,042,095	11 / 13
2026-08-27	$3.37	$4,452,042,095	11 / 13
2026-08-28	$3.37	$4,452,042,095	11 / 13
2026-08-29	$3.37	$4,452,067,095	12 / 13
2026-08-30	$3.37	$4,452,067,095	12 / 13
2026-08-31	$3.37	$4,452,067,095	12 / 13
2026-09-01	$3.37	$4,452,067,095	12 / 13
2026-09-02	$3.37	$4,452,067,095	12 / 13
2026-09-03	$3.37	$4,452,067,095	12 / 13
2026-09-04	$3.37	$4,452,067,095	12 / 13
2026-09-05	$3.37	$4,452,067,095	12 / 13
2026-09-06	$3.37	$4,452,067,095	12 / 13
2026-09-07	$3.37	$4,452,067,095	12 / 13
2026-09-08	$3.37	$4,452,067,095	12 / 13
2026-09-09	$3.37	$4,452,067,095	12 / 13
2026-09-10	$3.37	$4,452,067,095	12 / 13
2026-09-11	$3.37	$4,452,067,095	12 / 13
2026-09-12	$3.36	$4,452,053,963	12 / 13
2026-09-13	$3.36	$4,452,053,963	12 / 13
2026-09-14	$3.36	$4,452,053,963	12 / 13
2026-09-15	$3.36	$4,452,067,095	12 / 13
2026-09-16	$3.36	$4,452,067,095	12 / 13
2026-09-17	$3.36	$4,452,067,095	12 / 13
2026-09-18	$3.36	$4,452,067,095	12 / 13
2026-09-19	$3.36	$4,452,067,095	12 / 13
2026-09-20	$3.36	$4,452,067,095	12 / 13
2026-09-21	$3.36	$4,452,067,095	12 / 13
2026-09-22	$3.36	$4,452,067,095	11 / 13
2026-09-23	$3.36	$4,452,067,095	11 / 13
2026-09-24	$3.36	$4,452,067,095	11 / 13
2026-09-25	$3.36	$4,452,067,095	11 / 12
2026-09-26	$3.35	$4,450,379,595	11 / 12
2026-09-27	$3.35	$4,450,379,595	11 / 12
2026-09-28	$3.35	$4,450,379,595	11 / 12
2026-09-29	$3.35	$4,450,379,595	11 / 12
2026-09-30	$3.35	$4,450,379,595	11 / 12
2026-10-01	$3.35	$4,450,379,595	11 / 12
2026-10-02	$3.35	$4,450,379,595	11 / 12
2026-10-03	$3.35	$4,450,379,595	11 / 12
2026-10-04	$3.35	$4,450,379,595	11 / 12
2026-10-05	$3.35	$4,450,379,595	11 / 12
2026-10-06	$3.35	$4,450,379,595	11 / 12
2026-10-07	$3.36	$4,448,792,560	11 / 12
2026-10-08	$3.35	$4,439,103,731	12 / 13
2026-10-09	$3.34	$4,436,691,966	12 / 13
2026-10-10	$3.34	$4,436,691,966	12 / 13
2026-10-11	$3.35	$4,437,576,407	12 / 14
2026-10-12	$3.35	$4,437,576,407	12 / 14
2026-10-13	$3.34	$4,433,580,584	12 / 14
2026-10-14	$3.34	$4,433,680,584	12 / 14
2026-10-15	$3.32	$4,431,531,933	12 / 14
2026-10-16	$3.32	$4,431,531,933	12 / 14
2026-10-17	$3.32	$4,431,531,933	12 / 14
2026-10-18	$3.31	$4,428,599,160	12 / 14
2026-10-19	$3.31	$4,428,599,160	12 / 14
2026-10-20	$3.30	$4,417,702,295	12 / 14
2026-10-21	$3.29	$4,411,957,850	12 / 14
2026-10-22	$3.29	$4,411,957,850	12 / 14
2026-10-23	$3.29	$4,411,957,850	12 / 14
2026-10-24	$3.29	$4,411,957,850	12 / 14

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	13	1
2026-06-01	5	12	1
2026-07-01	4	11	1
2026-08-01	7	11	1
2026-09-01	7	10	1
2026-10-01	8	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 11 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 7 · prior Aug 5

$57.00 → $49.00-14.0%

Melius ResearchOct 6

$44.00New observation · no comparable prior

BarclaysOct 6 · prior Aug 5

$54.00 → $47.00-13.0%

Evercore ISISep 25 · prior Aug 5

$56.00 → $45.00-19.6%

$0$31.35$62.70

0 raises · 3 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Capex stays between $110 million and $125 million in 2026Capital expenditures: $23.5M
Free cash flow reaches at least $375 million in 2026Free cash flow: $179.3M
Operating margin recovers toward 11% by FY26 endPublished status: Under Pressure
Revenue stays near $4.39 billion in 2026Revenue: $1.154B

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-48.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Fortune Brands Innovations outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is an execution-recovery thesis in an industrial business, not a clear durable compounder today. The thesis state is watch, with medium confidence, elevated risk, and fragile earnings quality.

What's priced into Fortune Brands Innovations

FBIN is described as cheap versus peers, but the expectations gap is negative, meaning expectations appear demanding relative to the model’s view. The priced-in assessment says weak execution is recognized, while the broader combination of expensive valuation, weak execution, and turbulence is not concentrated in the current setup.

What the fundamentals likely do

Near term, reported results remain uneven: revenue rose between the cited quarters, while GAAP operating income moved from profit to loss. Adjusted operating income improved year over year in Q2 2026, but management’s execution and cost priorities show mixed progress, and full-year free cash flow guidance was reduced. Recent earnings surprises have been erratic and trending down, while the October impairment update and CFO transition add uncertainty.

What Fortune Brands Innovations hinges on

The multi-year view hinges on whether management can turn its repeated focus on execution, efficiency, and core businesses into stronger reported profitability and cash flow. Near term, a guidance cut would be a meaningful negative; continued earnings strength from sector peers could support the industrial backdrop, while misses or lower guidance from those peers would remove that support.